secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-06-23T21:02:45+00:00
Accession:  0001104659-26-076857
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma SVP Áine Miller to depart Nov 15, 2026 as part of restructuring
--------------------------------------------------------------------------------

- Dr. Miller, SVP Development and Head of Ireland Office, will terminate on Nov 15, 2026.
- Termination is part of the restructuring announced by the Company in March 2026.
- Company will make a special pension contribution of $250,000 within 30 days of termination.
- Dr. Miller received a grant of 18,750 RSUs for continued service through the Termination Date.
- Compromise agreement and side letter entered into on June 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/0001104659-26-076857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/tm2618538d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer